Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
In the latest session, Vertex Pharmaceuticals, Inc (NASDAQ: VRTX) closed at $429.82 up 1.37% from its previous closing price of $424.0. In other words, the price has increased by $1.37 from its previous closing price. On the day, 1.55 million shares were traded. VRTX stock price reached its highest trading level at $431.4999 during the session, while it also had its lowest trading level at $424.12.
Ratios:
For a deeper understanding of Vertex Pharmaceuticals, Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 17.32 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 32.68. For the most recent quarter (mrq), Quick Ratio is recorded 2.00 and its Current Ratio is at 2.36. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.11.
Upgrades & Downgrades
In the most recent recommendation for this company, Scotiabank on November 13, 2025, initiated with a Sector Outperform rating and assigned the stock a target price of $495.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 20 ’25 when CARNEY LLOYD bought 800 shares for $426.36 per share.
Atkinson Edward Morrow III sold 2,500 shares of VRTX for $1,086,450 on Nov 17 ’25. The EVP, Chief Technical Ops. Off. now owns 16,852 shares after completing the transaction at $434.58 per share. On Nov 14 ’25, another insider, LEIDEN JEFFREY M, who serves as the Executive Chairman of the company, sold 53,604 shares for $440.72 each. As a result, the insider received 23,624,306 and left with 24,026 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VRTX now has a Market Capitalization of 110201831424 and an Enterprise Value of 104601231360. As of this moment, Vertex’s Price-to-Earnings (P/E) ratio for their current fiscal year is 30.29, and their Forward P/E ratio for the next fiscal year is 21.19. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.29 while its Price-to-Book (P/B) ratio in mrq is 6.30. Its current Enterprise Value per Revenue stands at 8.923 whereas that against EBITDA is 22.2.
Stock Price History:
The Beta on a monthly basis for VRTX is 0.32, which has changed by -0.08730841 over the last 52 weeks, in comparison to a change of 0.1177547 over the same period for the S&P500. Over the past 52 weeks, VRTX has reached a high of $519.68, while it has fallen to a 52-week low of $362.50. The 50-Day Moving Average of the stock is 4.13%, while the 200-Day Moving Average is calculated to be -3.09%.
Shares Statistics:
For the past three months, VRTX has traded an average of 1.51M shares per day and 1444380 over the past ten days. A total of 253.95M shares are outstanding, with a floating share count of 253.05M. Insiders hold about 0.26% of the company’s shares, while institutions hold 94.54% stake in the company. Shares short for VRTX as of 1763078400 were 4006159 with a Short Ratio of 2.74, compared to 1760486400 on 3555766. Therefore, it implies a Short% of Shares Outstanding of 4006159 and a Short% of Float of 1.78.
Earnings Estimates
The stock of Vertex Pharmaceuticals, Inc (VRTX) is currently in the spotlight, with 23.0 analysts actively rating and assessing its market standing.The consensus estimate for the next quarter is $4.89, with high estimates of $5.48 and low estimates of $4.29.
Analysts are recommending an EPS of between $19.15 and $17.2 for the fiscal current year, implying an average EPS of $18.45. EPS for the following year is $20.18, with 25.0 analysts recommending between $23.75 and $18.15.
Revenue Estimates
A total of 27 analysts believe the company’s revenue will be $3.18B this quarter.It ranges from a high estimate of $3.35B to a low estimate of $3.1B. As of . The current estimate, Vertex Pharmaceuticals, Inc’s year-ago sales were $2.91BFor the next quarter, 27 analysts are estimating revenue of $3.14B. There is a high estimate of $3.27B for the next quarter, whereas the lowest estimate is $2.99B.
A total of 29 analysts have provided revenue estimates for VRTX’s current fiscal year. The highest revenue estimate was $12.22B, while the lowest revenue estimate was $11.9B, resulting in an average revenue estimate of $11.99B. In the same quarter a year ago, actual revenue was $11.02BBased on 28 analysts’ estimates, the company’s revenue will be $13.05B in the next fiscal year. The high estimate is $14.13B and the low estimate is $12.05B.
